Abstract: Compositions comprising a TMEM16F inhibitor, an anti-cancer agent, and a pharmaceutically acceptable agent, and methods of treating of cancer comprising administering a TMEM16F inhibitor are provided herein.

Abstract: Methods for intervening in conditions of active desmoplasia comprise detecting increased levels of active alpha5-beta-1 integrin and the localization of this active integrin intracellularly away from three dimensional matrix adhesions within the stroma of affected tissues, as well as detecting the concomitant enhanced activity of focal adhesion kinase. Once active desmoplasia is detected, treatments may ensue, which induce a desmoplastic extracellular matrix to revert to a normal/innate phenotype, or which alter the standard of care to improve an outcome that would be less beneficial without the detection of a treatment-impeding desmoplasia condition. Liquid biopsies for detecting active desmoplasia are provided.

Abstract: The present disclosure provides polypeptides of netrin G1 (NetG1) and its cell surface receptor netrin G1 ligand (NGL1), and antibodies thereto, and methods of making such antibodies. The disclosure also provides uses of these NetG1 and NGL1 polypeptides, and antibodies thereto, in methods of treating cancers and diseases, including chronic fibrosis, inflammation, and inflammation-related diseases.

Abstract: The present disclosure provides methods of inducing desmoplastic stroma to express a normal phenotype by detecting increased levels of NetG1 or NGL1 in tumor or in desmoplastic stroma isolated from a human subject, and/or detecting NetG1 in circulating extracellular vesicles, and/or detecting increased pFAK in the stroma, and treating the human subject with a therapeutic regimen; and by detecting NetG1 in a microvesicle isolated from a human subject, and/or treating the human subject with a therapeutic regimen.

Abstract: The present disclosure provides extracellular matrix (ECM)/gel systems that have a substrate having a gel on a surface thereof, and a cell-derived matrix (CDM) on the surface of the gel, and methods of making ECM/gel systems, and methods of using ECM/gel systems to, for example, screen agents for anti-cancer or anti-fibrotic activity.

Abstract: The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.

Abstract: The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.